bitBiome selected to Global Hypergrowth Tokyo, A Global Late-Stage Scaling Program 

April 4, 2024 | Press Releases

TOKYO, March 27, 2024—bitBiome, Inc., a biotechnology company unlocking the potential of our planet’s microbes to power the future of the bioeconomy, has been selected as a supported company in the “Global Hypergrowth Tokyo Program 2024” organized by Startup Genome. Currently, bitBiome is not only operating in Japan but is also expanding its biomanufacturing business utilizing microbial genetic data in the United States and Europe. This expansion includes the establishment of a U.S. corporation, a global business development team, and a fermentation production team. Through the 10-month “Global Hypergrowth Tokyo Program 2024,” they aim to further expand globally and grow their business.

The Context for Hypergrowth

High-growth startups: a vector of economic, social, and environmental impact,

Hypergrowth focuses on high-growth startups, recognizing them as drivers of economic growth and competitiveness, and creators of sustainable jobs and societal wellbeing.

Significant gap of support for the fastest growing scaleups

The program addresses a significant support gap for fast-growing scaleups, as most efforts traditionally concentrate on early-stage startups.

Hypergrowth stage: going global

Hypergrowth acknowledges the challenges for startups expanding globally, offering a solution to navigate global expansion through introductions to deep overseas networks. As the primary challenge for scaleups is their limited access to executives with scaling and global commercialization expertise, Hypergrowth will provide 22 companies from Tokyo with access to global mentors, expert scaling advice from leading executives, go-to-market support, and connections to potential new customers and investors as they significantly increase their international expansion capabilities.

The companies selected are some of the most exciting scaleups in Tokyo, including many Deep Tech, healthtech, and AI companies. The cohort has raised close to $100 million USD in collective funding as they look to expand overseas, with customers based in the U.S., Europe, and Asia.

About bitBiome, Inc.

bitBiome is a biotechnology company unlocking the full potential of our planet’s microbes to power the future of the bioeconomy. bitBiome’s platform is built on their proprietary single-cell microbial genome analysis technology, bit-MAP ®, which has enabled the creation of bit-GEM: an extensive and groundbreakingly diverse microbial database of over 1.5 billion sequences, sourced primarily from environmental samples and containing sequences not present in public databases. Leveraging their expertise in bioinformatics and machine learning, the company also offers a comprehensive enzyme discovery and engineering platform, bit-QED, which encompasses the identification, assessment, and modification of enzymes through wet lab evaluation and directed evolution. bitBiome is committed to improving existing biomanufacturing industries and creating new ones by delivering sequences and enzymes that cannot be found anywhere else. To learn more about bitBiome’s platform and services, visit